

Short Note

2-Fluoro-*N*-methyl-*N*-({(3*S*,4*S*)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1*H*-isochromen-3-yl}methyl)ethanamine

Catharina Neudorfer ^{1,2,*}, Karem Shanab ^{1,2}, Wolfgang Holzer ², Christina Rami-Mark ¹, Markus Mitterhauser ¹, Wolfgang Wadsak ¹ and Helmut Spreitzer ^{2,*}

- ¹ Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; E-Mails: karem.shanab@gmail.com (K.S.); christina.rami-mark@meduniwien.ac.at (C.R.-M.); markus.mitterhauser@meduniwien.ac.at (M.M.); wolfgang.wadsak@meduniwien.ac.at (W.W.)
- ² Division of Drug Synthesis, Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; E-Mail: wolfgang.holzer@univie.ac.at
- * Authors to whom correspondence should be addressed;
 E-Mails: catharina.neudorfer@gmail.com (C.N.); helmut.spreitzer@univie.ac.at (H.S.);
 Tel.: +43-4277-55629 (C.N.); +43-4277-55621 (H.S.); Fax: +43-4277-855629 (C.N.);
 +43-4277-855621 (H.S.).

Academic Editor: Norbert Haider

Received: 13 April 2015 / Accepted: 6 May 2015 / Published: 8 May 2015

Abstract: Starting from *N*-methyl-1- $\{(3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1$ *H* $-isochromen-3-yl}methanamine (1) target compound 2 is prepared using a mild, direct alkylation approach with 2-fluoroethyl trifluoromethanesulfonate.$

Keywords: NET; PET; PHOXI

Introduction

Since norepinephrine (NE) represents a fundamental neurochemical messenger, its accurate regulation is of major importance. Thus the norepinephrine transporter (NET), responsible for the NE equilibrium in the synaptic cleft, is considered to be involved in a variety of neurological/psychiatric disorders [1,2], but also plays a pivotal role in cardiovascular [1–3], and metabolic diseases [3–5].


To obtain information about the transporter abundance and density in healthy and pathological living human brains, the most suitable and accurate technique today is positron emission tomography (PET). It represents a non-invasive molecular imaging technique and a suitable approach towards the collection of missing data in the living organism. Moreover, it enables direct quantification of receptor or transporter densities *in vivo*. However, in order to understand the molecular changes of the noradrenergic system via PET, prior suitable NET-PET radioligands need to be prepared. Non-radioactive reference compounds serve as a basis for preclinical investigations of the respective target.

In this regard, several 3,4-dihydro-1*H*-isochromene derivatives were synthesized [6,7], which have been described by our research group as potential precursors and reference compounds for PET based investigations of the NET. In continuation of these previous studies, we are reporting in this paper the synthesis of 2-fluoro-*N*-methyl-*N*-{[(3S,4S)-4-(2-methylphenoxy)-3,4-dihydro-1*H*-isochromen-3-yl]methyl}ethanamine (FE@PHOXI2) (**3**), a reference compound for the NET for future preclinical testing.

Results and Discussion

Derivative 1 was made accessible by reacting 1*H*-isochromen-4(3*H*)-one in a Mannich reaction with dimethylamine hydrochloride and paraformaldehyde, followed by reduction of the keto group into an alcohol group with L-Selectride. Subsequent reaction with 1-fluoro-2-(trifluoromethyl)benzene then afforded N,N-dimethyl-1-{(3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1*H*-isochromen-3-yl}methanamine, which after *N*-demethylation yielded compound 1.

For the preparation of derivative **2**, a mild synthesis approach was chosen, in which freshly prepared 2-fluoroethyl trifluoromethanesulfonate [8] was reacted with the -prior activated- secondary amine (1) at 0 $^{\circ}$ C (Scheme 1). Due to the high reactivity of triflates, the alkylation was carried out in less than ten minutes while the temperature was slowly raised to 25 $^{\circ}$ C.



Scheme 1. Reaction of *N*-methyl-1-((3*S*,4*S*)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1*H*-isochromen-3-yl)methanamine to 2-Fluoro-*N*-methyl-*N*-(((3*S*,4*S*)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1*H*-isochromen-3-yl)methyl)ethanamine (FE@PHOXI2).

Experimental Section

General Information

The NMR spectra were recorded from a CDCl₃ solution on a Bruker Avance III 400 spectrometer (Billerica, MA, USA) (400 MHz for ¹H, 100 MHz for ¹³C, 40 MHz for ¹⁵N, 376 MHz for ¹⁹F) at 25 °C.

The center of the solvent (residual) signal was used as an internal standard which was related to TMS with δ 7.26 ppm (¹H in CDCl₃), and δ 77.0 ppm (¹³C in CDCl₃). ¹⁹F-NMR spectra were referenced by absolute referencing via Ξ ratio. Digital resolutions were 0.25 Hz/data point in the ¹H and 0.3 Hz/data point in the ¹³C-NMR spectra. Coupling constants (*J*) are quoted in Hz. The following abbreviations were used to show the multiplicities: s: singlet, d: doublet, t: triplet, q: quadruplet, dd: doublet of doublet, m: multiplet. Mass spectra were obtained on a Shimadzu QP 1000 instrument (Kyoto, Japan, EI, 70 eV), high-resolution mass spectrometry (HRMS) was carried out on a maXis HD ESI-Qq-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) in the positive-ion mode by direct infusion. Compound purity: all compounds synthesized featured a purity of at least 95%.

2-Fluoro-N-methyl-N-{[(3S,4S)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine (FE@PHOXI2)

To a suspension of *N*-methyl-1-((3S,4S)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1*H*isochromen-3-yl)methanamine (0.07 g, 0.22 mmol) in dry ACN (5 mL) was added triethylamine (0.05 mL, 0.33 mmol) under argon atmosphere. After cooling the mixture to 0 °C, 2-fluoroethyl trifluoromethansulfonate (0.03 mL, 0.26 mmol) was slowly added. The solution was stirred for 10 min during which the temperature was allowed to warm to 20 °C. After evaporation of the solvent, the crude reaction product was purified by column chromatography (silica gel 60, 7% MeOH in CH₂Cl₂).

Yield: 55 mg (65%), light yellow oil.

¹H-NMR (400 MHz, CDCl₃): δ (ppm) 2.42 (s, 3H, CH₂NCH₃CH₂CH₂F), 2.73–2.75 (m, 1H, CH₂NCH₃CH₂CH₂F), 2.85 (dd, *J* = 13.3 Hz and 6.6 Hz, 1H, CH₂NCH₃CH₂CH₂F), 2.88–2.91 (m, 1H, CH₂NCH₃CH₂CH₂F) 2.98 (dd, *J* = 13.3 Hz and 6.4 Hz, 1H, CH₂NCH₃CH₂CH₂F), 4.12 (dt, *J* = 2.3 Hz and 6.5 Hz, 1H, isochr 3-CH), 4.46 (t, *J* = 4.9 Hz, 1H, CH₂NCH₃CH₂CH₂F), 4.58 (t, *J* = 4.9 Hz, 1H, CH₂NCH₃CH₂CH₂F), 5.50 (t, *J* = 2.3 Hz, 1H, isochr 1-CH₂), 5.05 (t, *J* = 15.3 Hz, AB-system, 1H, isochr 1-CH₂), 5.50 (t, *J* = 2.3 Hz, 1H, isochr 4-CH), 7.00–7.04 (m, 1H, benz 4-CH), 7.07–7.12 (m, 3H, isochr 8-CH, isochr 5-CH, isochr 6-CH), 7.26–7.30 (m, 1H, isochr 7-CH), 7.35–7.37 (m, 1H, isochr-6-CH), 7.46–7.51 (m, 1H, benz 5-CH), 7.52–7.54 (m, 1H, benz 3-CH).

¹³C-NMR (100 MHz, CDCl₃): δ (ppm) 43.4 (CH₂N<u>C</u>H₃CH₂CH₂F), 57.4 (<u>C</u>H₂NCH₃CH₂CH₂F), 57.9 (d, J = 19.8 Hz, CH₂NCH₃<u>C</u>H₂CH₂F), 67.3 (isochr 1-<u>C</u>H₂), 72.7 (isochr 4-<u>C</u>H), 74.6 (isochr 3-<u>C</u>H), 81.8 (d, J = 167.8 Hz, CH₂NCH₃CH₂<u>C</u>H₂F), 116.4 (benz 6-<u>C</u>H), 120.6 (q, J = 30.5 Hz, benz 2-C), 120.8 (benz 4-<u>C</u>H), 123.5 (q, J = 272.6 Hz, benz <u>C</u>F₃), 124.3 (isochr 8-<u>C</u>H), 126.5 (isochr 6-<u>C</u>H), 127.2 (q, J = 5.3 Hz, benz 3-<u>C</u>H), 128.7 (isochr 7-<u>C</u>H), 128.9 (isochr 5-<u>C</u>H), 131.2 (isochr 4a-C), 132.9 (benz 5-<u>C</u>H), 135.3 (isochr 8a-C), 155.9 (q, J = 1.7 Hz, benz 1-C).

¹⁹F-NMR (471 MHz, CDCl₃): δ (ppm) –61.8 (s, benz C<u>F</u>), –219.3 (m, CH₂NCH₃CH₂CH₂<u>F</u>).

MS: *m/z* (%) 383 (M⁺, 1), 350 (1), 322 (1), 218 (1), 175 (1), 132 (4), 115 (3), 104 (4), 90 (100).

HRMS: *m/z* calculated for C₂₀H₂₂F₄NO₂ [M+H]⁺: 384.1581. Found: 384.1532.

Author Contributions

Catharina Neudorfer: Responsible for the performance of the syntheses and writing; Karem Shanab: Contributions to syntheses and experimental procedures; Wolfgang Holzer: Performance of the NMR analyses; Christina Rami-Mark: Designed parts of the research; Markus Mitterhauser: Designed parts of the research and proofread the manuscript; Wolfgang Wadsak: Designed parts of the research and proofread the manuscript; Helmut Spreitzer: Conceived and supervised the syntheses.

Conflicts of Interest

The authors declare no conflict of interest.

References

- 1. Sung, U.; Apparsundram, S.; Galli, A.; Kahlig, K.M.; Savchenko, V.; Schroeter, S.; Quick, M.W.; Blakely, R.D. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. *J. Neurosci.* **2003**, *23*, 1697–1709.
- Kim, C.H.; Hahn, M.K.; Joung, Y.; Anderson, S.L.; Steele, A.H.; Mazei-Robinson, M.S.; Gizer, I.; Teicher, M.H.; Cohen, B.M.; Robertson, D.; *et al.* A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. *Proc. Natl. Acad. Sci. USA* 2006, *103*, 19164–19169.
- 3. Hahn, M.K.; Robertson, D.; Blakely, R.D. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. *J. Neurosci.* **2003**, *23*, 4470–4478.
- Mirbolooki, M.R.; Upadhyay, S.K.; Constantinescu, C.C.; Pan, M.L.; Mukherjee, J. Adrenergic pathway activation enhances brown adipose tissue metabolism: A [¹⁸F]FDG PET/CT study in mice. *Nucl. Med. Biol.* 2014, *41*, 10–16.
- Lin, S.L.; Fan, X.; Yeckel, C.W.; Weinzimmer, D.; Mulnix, T.; Gallezot, J.D.; Carson, R.E.; Sherwin, R.S.; Ding, Y.S. *Ex vivo* and *in vivo* Evaluation of the Norepinephrine Transporter Ligand [¹¹C]MRB for Brown Adipose Tissue Imaging. *Nucl. Med. Biol.* 2012, *39*, 1081–1086.
- 6. Neudorfer, C. Development of Novel Precursors and Reference Compounds for PET Based Investigations Targeting the Norepinephrine Transporter and Monoamine Oxidase B. Ph.D. Thesis, University of Vienna, Vienna, Austria, November 2014.
- Hudson, S.; Kiankarimi, M.; Eccles, W.; Mostofi, Y.S.; Genicot, M.J.; Dwight, W.; Fleck, B.A.; Gogas, K.; Wade, W.S. Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. *Bioorg. Med. Chem. Lett.* 2008, *18*, 4495–4498.
- Claremon, D.A.; Zhuang, L.; Leftheris, K.; Tice, C.M.; Xu, Z.; Ye, Y.; Singh, S.B.; Cacatian, S.; Zhao, W.; Himmelsbach, F.; *et al.* Cyclic Inhibitors of 11beta-Hydroxysteroid Dehydrogenase 1. PCT Int. Appl. WO 2009134392 A1, November 2009.

 \bigcirc 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).